Citations

Showing 10 of 108119 citations.

Identification of a Cryptic t(8;20;21)(q22;p13;q22) Resulting in RUNX1T1/RUNX1 Fusion in a Patient with Newly Diagnosed Acute Myeloid Leukemia
Macke, Erica L. , Meyer, Reid G., Hoppman, Nicole L., Greipp, Patricia T. , Xu, Xinjie , Shafer, Danielle , He, Rui , Peterson, Jess F. , Peterson, Jess F , Greipp, Patricia T , Ketterling, Rhett P. , Baughn, Linda B.

Mayo Clinic

Laboratory Medicine | October 19, 2021 | Volume: 53 | Issue: 4 | Pages: e87-e90

10.1093/labmed/lmab105 | PMID 34791328 Get It

Abstract The detection of recurrent genetic abnormalities in acute myeloid leukemia (AML), including RUNX1T1/RUNX1 gene fusion, is critical for optimal medical management. Herein, we report a 45 year old woman with newly diagnosed AML and conventional chromosome studies that revealed an apparently balanced t(8;20)(q22;p13) in all 20 metaphases analyzed. A RUNX1T1/RUNX1 dual-color dual-fusion fluorescence in situ hybridization (FISH) probe set was subsequently performed and revealed a RUNX1T1/RUNX1 gene fusion. Metaphase FISH studies performed on abnormal metaphases revealed a cryptic, complex translocation resulting in RUNX1T1/RUNX1 fusion, t(8;20;21)(q22;p13;q22). This case study shows the importance of performing FISH studies or other high-resolution genetic testing concurrently with conventional chromosome studies for the detection of cryptic recurrent gene fusions in AML, particularly a focused genetic evaluation such as RUNX1T1/RUNX1 gene fusion, when specific abnormalities involving 8q22 are identified.
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases
Benatar, Michael , Wuu, Joanne , McHutchison, Caroline , Boeve, Bradley F. , Petersen, Ronald C. , Ross, Christopher A. , Rosen, Howard J. , Arias, Jalayne J. , Fradette, Stephanie , Stanislaw, Christine , Abrahams, Sharon, Cosentino, Stephanie , Grignon, Anne‐Laure , Rohrer, Jonathan D. , Al-Chalabi, Ammar, Workshop, First International Pre-Symptomatic ALS, Al-Chalabi, Ammar, Andersen, Peter M, Dave, Kuldip D. , Ferguson, Toby A. , Floeter, Mary-Kay, Grossman, Murray, Gubitz, Amelie K., Kaufman, Petra, Ber, Isabelle Le , Lee, Suzee, Malaspina, Andrea , Nicholson, Katie, Robinson, Richard , Stanislaw, Christine, Tatton, Nadine , Thakur, Neil , Weishaupt, Jochen H. , McDermott, Michael P. , Boeve, Brad , Ross, Christopher A , Stanislaw, Christine , Andersen, Peter Munch , Granit, Volkan , Turner, Martin R , Rohrer, Jonathan D , Postuma, Ronald B. , McDermott, Michael , Shefner, Jeremy M. , Finkel, Richard S. , McMillan, Corey T. , Grossman, Murray , Al-Chalabi, Ammar, Turner, Martin R. , Workshop, First International Pre-Symptomatic ALS, Al-Chalabi, Ammar, Andersen, Peter M, Floeter, Mary Kay, Gendron, Tania F. , Nicholson, Katie, Stanislaw, Christine

Mayo Clinic

Brain | October 19, 2021 | Volume: 145 | Issue: 1 | Pages: 27-44

10.1093/brain/awab404 | PMID 34677606 Get It

Abstract Significant progress has been made in understanding the pre-symptomatic phase of amyotrophic lateral sclerosis. While much is still unknown, advances in other neurodegenerative diseases offer valuable insights. Indeed, it is increasingly clear that the well-recognized clinical syndromes of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, spinal muscular atrophy and frontotemporal dementia are also each preceded by a pre-symptomatic or prodromal period of varying duration, during which the underlying disease process unfolds, with associated compensatory changes and loss of inherent system redundancy. Key insights from these diseases highlight opportunities for discovery in amyotrophic lateral sclerosis. The development of biomarkers reflecting amyloid and tau has led to a shift in defining Alzheimer’s disease based on inferred underlying histopathology. Parkinson’s disease is unique among neurodegenerative diseases in the number and diversity of non-genetic biomarkers of pre-symptomatic disease, most notably REM sleep behaviour disorder. Huntington’s disease benefits from an ability to predict the likely timing of clinically manifest disease based on age and CAG-repeat length alongside reliable neuroimaging markers of atrophy. Spinal muscular atrophy clinical trials have highlighted the transformational value of early therapeutic intervention, and studies in frontotemporal dementia illustrate the differential role of biomarkers based on genotype. Similar advances in amyotrophic lateral sclerosis would transform our understanding of key events in pathogenesis, thereby dramatically accelerating progress towards disease prevention. Deciphering the biology of pre-symptomatic amyotrophic lateral sclerosis relies on a clear conceptual framework for defining the earliest stages of disease. Clinically manifest amyotrophic lateral sclerosis may emerge abruptly, especially among those who harbour genetic mutations associated with rapidly progressive amyotrophic lateral sclerosis. However, the disease may also evolve more gradually, revealing a prodromal period of mild motor impairment preceding phenoconversion to clinically manifest disease. Similarly, cognitive and behavioural impairment, when present, may emerge gradually, evolving through a prodromal period of mild cognitive impairment or mild behavioural impairment before progression to amyotrophic lateral sclerosis. Biomarkers are critically important to studying pre-symptomatic amyotrophic lateral sclerosis and essential to efforts to intervene therapeutically before clinically manifest disease emerges. The use of non-genetic biomarkers, however, presents challenges related to counselling, informed consent, communication of results and limited protections afforded by existing legislation. Experiences from pre-symptomatic genetic testing and counselling, and the legal protections against discrimination based on genetic data, may serve as a guide. Building on what we have learned—more broadly from other pre-symptomatic neurodegenerative diseases and specifically from amyotrophic lateral sclerosis gene mutation carriers—we present a road map to early intervention, and perhaps even disease prevention, for all forms of amyotrophic lateral sclerosis.
Predictors of Left Ventricular Outflow Tract Obstruction After Transcatheter Mitral Valve Replacement in Severe Mitral Annular Calcification: An Analysis of the Transcatheter Mitral Valve Replacement in Mitral Annular Calcification Global Registry
Sabbagh, Abdallah El , Al‐Hijji, Mohammed , Wang, Dee Dee , Eleid, Mackram F. , Ureña, Marina , Himbert, Dominique , Chakravarty, Tarun , Fang, Hao , Zahr, Firas , Dvir, Danny , Sardar, Muhammad , Cheema, Asim N. , Alnasser, Sami , Iyer, Vijay , Kaddissi, Georges, Webb, John G. , Makkar, Raj , Vahanian, Alec , Rihal, Charanjit S. , Eleid, Mackram F , Nejjari, Mohammed , Dvir, Danny , Rihal, Charanjit, Guerrero, Mayra E , Al-Hijji, Mohammed A , Wang, Dee Dee , Holzhey, David Michael , Pershad, Ashish , Nejjari, Mohammed , O’Neill, William W. , Rihal, Charanjit S. , Guerrero, Mayra

Mayo Clinic

Circulation: Cardiovascular Interventions | October 19, 2021 | Volume: 14 | Issue: 10 | Pages: No page available

10.1161/circinterventions.121.010854 | PMID 34665654 Get It

Background: Several studies have evaluated preprocedural imaging predictors of left ventricular outflow tract obstruction (LVOTO) after transcatheter mitral valve replacement. The patient cohorts in these studies were heterogeneous and included patients with transcatheter mitral valve replacement in failed bioprostheses, annuloplasty rings, and severe mitral annular calcification (MAC). The goal of this study was to evaluate predictors of LVOTO specific to patients undergoing valve-in-MAC. Methods: This study included patients with severe MAC who underwent valve-in-MAC and had optimal quality preprocedural multidetector row computed tomography scans eligible for retrospective analysis. Baseline demographic, echocardiographic, and procedural data on these patients were collected. multidetector row computed tomography parameters were analyzed for association with LVOTO, defined as increase in mean LVOT gradient by ≥10 mm Hg with accompanying hemodynamic instability. Results: Seventy-one patients with optimal preprocedural computed tomography scans were included in this study (mean age, 72.5±13.5 years), 9 of which developed LVOTO (all female). Baseline mean LVOT area, neo-LVOT area (145.3 versus 270.9 mm 2 ; P =0.006), indexed neo-LVOT area (90.1 versus 157.4; P =0.05), and virtual transcatheter heart valve to septum distance (3.1 versus 6.9 mm; P =0.002) were lower in the LVOTO group. Expected % LVOT area reduction was higher in the latter group (58.3 versus 42.7%; P =0.008). In the univariable analysis, the baseline mean LVOT area, neo-LVOT area, indexed neo-LVOT area, and valve to septum distance were all significantly associated with LVOTO. Conclusions: The systolic mean LVOT area, neo-LVOT area, indexed neo-LVOT, expected percentage LVOT area reduction, and the valve to septum distance were associated with LVOTO after valve-in-MAC.
Comparison between same‐day discharge and overnight stay after atrial fibrillation ablation: Systematic review and meta‐analysis
Prasitlumkum, Narut , Cheungpasitporn, Wisit , Chokesuwattanaskul, Ronpichai , Kewcharoen, Jakrin , Tokavanich, Nithi , Navaravong, Leenhapong , Jongnarangsin, Krit, Cheungpasitporn, Wisit , Chokesuwattanaskul, Ronpichai , Kewcharoen, Jakrin , Navaravong, Leenhapong , Prasitlumkum, Narut

Mayo Clinic

Pacing and Clinical Electrophysiology | October 19, 2021 | Volume: 44 | Issue: 12 | Pages: 2054-2066

10.1111/pace.14380 | PMID 34657314 Get It

AbstractBackgroundIn the modern era, atrial fibrillation (AF) ablation trend has been shifted toward same‐day discharge (SDD), from a traditional overnight stay. Yet, recent studies have not well stated the safety profiles which remained poor‐understood and dispersed. We hence performed systematic review and meta‐analysis to assess the adverse outcomes of SDD in comparison with an overnight stay.MethodsDatabases were searched through January 2021. Effect estimates from the individual studies were extracted and combined using random‐effects, generic inverse variance method of der Simonian and Laird. The primary outcomes included total cumulative complications and immediate complications following AF ablation.ResultsTen observational studies were met our inclusion criteria, comprising of total population of 11,660 patients, with SDD 51.3%. For total cumulative complications, there were no differences observed between SDD and overnight stay (5.2% vs. 6.2%: pooled OR 0.77: 95% CI 0.55–1.08, p = .13 with I2 = 27.1%). In addition, comparable immediate complications were also demonstrated (5.2 % vs. 4.3: pooled OR 1.08: 95% CI 0.72–1.62, p = .718, with I2 = 37.3 %).ConclusionOur study suggested that SDD had similar complication rates, both total cumulative and immediate outcomes, compared with overnight stay in selected patients following AF ablation. Nevertheless, randomized control trials are warranted to validate the findings.
Faculty Opinions recommendation of Antepartum and postpartum anemia: a narrative review.
Sviggum, Hans P.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 19, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.740028388.793588935 Get It

Anastrozole Regulates Fatty Acid Synthase in Breast Cancer
Cairns, Junmei , Ingle, James N. , Goetz, Matthew P. , Weinshilboum, Richard M. , Gao, Huanyao , Bari, Mehrab Ghanat, Wang, Liewei , Goetz, Matthew P , Gao, Huanyao , Ingle, J , Kalari, Krishna R. , Weinshilboum, Richard M. , Li, Hu

Mayo Clinic

Molecular Cancer Therapeutics | October 19, 2021 | Volume: 21 | Issue: 1 | Pages: 206-216

10.1158/1535-7163.mct-21-0509 | PMID 34667110 Get It

Abstract Our previous matched case–control study of postmenopausal women with resected early-stage breast cancer revealed that only anastrozole, but not exemestane or letrozole, showed a significant association between the 6-month estrogen concentrations and risk of breast cancer. Anastrozole, but not exemestane or letrozole, is a ligand for estrogen receptor α. The mechanisms of endocrine resistance are heterogenous and with the new mechanism of anastrozole, we have found that treatment of anastrozole maintains fatty acid synthase (FASN) protein level by limiting the ubiquitin-mediated FASN degradation, leading to increased breast cancer cell growth. Mechanistically, anastrozole decreases the guided entry of tail-anchored proteins factor 4 (GET4) expression, resulting in decreased BCL2-associated athanogene cochaperone 6 (BAG6) complex activity, which in turn, prevents RNF126-mediated degradation of FASN. Increased FASN protein level can induce a negative feedback loop mediated by the MAPK pathway. High levels of FASN are associated with poor outcome only in patients with anastrozole-treated breast cancer, but not in patients treated with exemestane or letrozole. Repressing FASN causes regression of breast cancer cell growth. The anastrozole-FASN signaling pathway is eminently targetable in endocrine-resistant breast cancer.
Incidental Adrenal Lesions May Not Always Require Further Imaging Work-up
Baumgarten, Deborah A.

Mayo Clinic

Radiology | October 19, 2021 | Volume: 302 | Issue: 1 | Pages: 138-139

10.1148/radiol.2021212116 | PMID 34665036 Get It

CXC chemokine receptor 4 (CXCR4) targeted gold nanoparticles potently enhance radiotherapy outcomes in breast cancer
Bhattarai, Shanta, Mackeyev, Yuri , Venkatesulu, Bhanu Prasad , Singh, Pankaj K. , Mackeyev, Yuri , Bhattarai, Shanta, Krishnan, Sunil

Mayo Clinic

Nanoscale | October 19, 2021 | Volume: 13 | Issue: 45 | Pages: 19056-19065

10.1039/d1nr05385j | PMID 34757363 Get It

CXC chemokine receptor 4 (CXCR4) is overexpressed on most breast cancer cell surfaces including triple negative breast cancer (TNBC) which lacks traditional receptor overexpression.
Short-Term Lidocaine Infusion as a Nonsedative Option to Maintain Ventilator Synchrony During Opioid Tapering in a COVID-19 Patient
Barman, Ross , Clark, Kathryn J. , Olatoye, Oludare, Clark, Kathryn , Barman, Ross A

Mayo Clinic

Pain Medicine | October 19, 2021 | Volume: 23 | Issue: 3 | Pages: 592-595

10.1093/pm/pnab311 | PMID 34672352 Get It

Author response: Modulation of fracture healing by the transient accumulation of senescent cells
Saul, Dominik , Vos, Stephanie J. B. , Saul, Dominik , Monroe, David G. , Rowsey, Jennifer L. , Kosinsky, Robyn Laura , Vos, Stephanie J, Doolittle, Madison L. , Farr, Joshua N. , Khosla, Sundeep

Mayo Clinic

No container title available | October 19, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.69958.sa2 Get It